Vaccination
Controlled Access
Unmet Need
Dosing
Dosing¹
Posology & Method of AdministrationThe recommended dose is 200 mg taken orally twice daily.
Healthcare professionals should advise patients with PNH about the...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action (MoA)
Mechanism of Action (MoA)¹
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
The most commonly reported adverse reactions were upper respiratory tract infection (18.9%), headache (18.3%) and diarrhoea (11.0%). The most commonly reported serious adverse reaction was urinary tract infection (1.2%) 1 .Twitter Linkedin Facebook Pinterest Google plusClinical efficacy & safety
The efficacy and safety of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (APPLY-PNH)...
Twitter Linkedin Facebook Pinterest Google plusIndication
FABHALTA ® is indicated as monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have haemolytic anemia 1 .
FABHALTA® is the first and only Factor B inhibitor. FABHALTA® acts...
Twitter Linkedin Facebook Pinterest Google plusReimbursement
×